Printer Friendly

Articles from M2 Pharma (July 25, 2019)

1-16 out of 16 article(s)
Title Author Type Words
Baxter Wins US FDA Approval of Myxredlin, The First and Only Ready-To-Use Insulin for IV Infusion. 540
FDA approves nasal powder for severe hypoglycemia. 269
FDA Approves Pfizer's Biosimilar, Ruxience (rituximab-pvvr), for Certain Cancers and Autoimmune Conditions. 267
Frequency Therapeutics Completes USD 62m Series C Financing. 344
Gilead Presents New Findings on Profile of Descovy for Potential Use as HIV Pre-exposure Prophylaxis Compared with Truvada. 639
Global Stem Cell Therapy Market to Surpass USD 33.6bn by 2026. 504
Jubilant Cadista Pharmaceuticals recalls batch of Drospirenone and Ethinyl Estradiol Tablets. 163
LabCorp Expands Consumer-Initiated Test Offering. 659
Ligand Pharmaceuticals to acquire Ab Initio Biotherapeutics. 179
OnKure Executes License and Option Agreement with KDAc Therapeutics. 244
Seattle Genetics Eyes USD 440m Raise from Common Stock Offering. 300
Stratify Genomics reports another USD2.2m from Seed Series funding. 119
Thermo Fisher Scientific reports financial results for Q2 2019. Financial report 105
US Merck Presents Early Evidence on Extended Delivery of Investigational Anti-HIV-1 Agent Islatravir (MK-8591) via Subdermal Implant. 614
USFDA grants approval to Pfizer's Ruxience. 139
ViaCyte names new Directors. 190

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |